Falls of Neuse Management LLC (FNMLLC) is an industry-leading and employee-owned company engaged in the sale and distribution of welding supplies and automotive industrial coatings. Operations are based in multiple locations throughout the United States. FNMLLC is owned by two companies: American Welding & Gas, Inc. (AWG) and National Coatings & Supplies, Inc. (NCS). We provide management support services for both of these companies from our corporate headquarters in Raleigh, NC.

UPL Ltd. (NSE: UPL & BSE: 512070) is a global provider of sustainable agriculture products & solutions, with annual revenue exceeding $5 billion. As one of the top 5 agriculture solutions companies worldwide, our robust portfolio consists of biologicals and traditional crop protection solutions with more than 13,600 registrations. With a presence in more than 130 countries and more than 10,000 colleagues globally, we reach more than 90% of the world’s food basket. For more information about our integrated portfolio of solutions across the food value chain including seeds, post-harvest, as well as physical and digital services, please visit upl-ltd.com.

Mayne Pharma is an ASX-listed specialty pharmaceutical Company (ASX: MYX) focused on commercializing novel and generic pharmaceuticals. We offer patients better, safe and more accessible medicines. Mayne Pharma has a 40-year track record of innovation and success in developing oral drug delivery systems. These technologies have been successfully commercialized in numerous products that continue to be marketed around the world. Mayne Pharma also has a full service contract development and manufacturing organizations (CDMO) servicing clients worldwide: Mayne Contract Services is based in Salisbury, SA, Australia Here are some key facts about our company: • 400+ staff • A$500m+ market cap • A$400m+ in revenue (FY22) • A product portfolio of 90+ marketed products globally The Company's corporate values are: • Empowerment – encouraging everyone to take initiative, enabling growth and achievement. • Passion – showing pride, enthusiasm and dedication in everything we do. • Creativity – delivering value and striving to connect new ideas with business realities. • Agility – operating with timeliness as well as mental, emotional and physical flexibility. • Integrity – maintaining high ethical standards, demonstrating honesty, and respecting fairness by doing the right thing, even when no one is looking. • Accountability – accepting our individual and team responsibilities, meeting our commitments, and acknowledging and learning from mistakes. To learn more, visit us at www.maynepharma.com. Our social media policy: https://bit.ly/3py3L1e Any communication you receive from Mayne Pharma will never come from a personal email domain or chat service such as "gmail" or "Google Chat". All official communication from Mayne Pharma will be received from our company email domain - @maynepharma.com.

At Piedmont Chemical Industries, we’ve used the same formula for success for 80 years: focus on developing and manufacturing high quality textile and specialty chemicals that provide innovative solutions to our customers’ problems and maintaining the best customer support and service in the industry. Since our beginning in 1938, Piedmont has evolved into 5 different production sites in the Southeast offering a wide range of manufacturing capabilities. Family is important to us at Piedmont, and we’re proud that we remain owned and operated by the family of our founder.

Marken is the clinical and advanced therapy subsidiary of UPS Healthcare. With Marken, Polar Speed and BOMI Group included, the UPS Healthcare network consists of 200+ locations worldwide. Marken offers a state-of-the-art GMP-compliant depot network and logistic hubs for clinical drug product storage and distribution in 60 locations worldwide, while maintaining the leading position for cell and gene therapy services, direct-to-patient and home healthcare services, biological sample shipments and biological kit production. Marken’s dedicated 2,600+ staff members manage 180,000 drug product and biological sample shipments every month at all temperature ranges in more than 220 countries and territories and have orchestrated 16,000+ home healthcare visits. Additional services such as ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry. Delivering What Matters From Clinical to Commercial.

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Jowat SE with headquarters in Detmold is one of the leading suppliers of industrial adhesives. These are mainly used in woodworking and furniture manufacture, in the paper and packaging industry, for graphic arts, in the textile, automotive as well as in the electrical industry. The company was founded in 1919 and has manufacturing sites in Germany in Detmold and Elsteraue, plus three other producing subsidiaries, Jowat Corporation in the USA, Jowat Swiss AG and the Jowat Manufacturing in Malaysia. The supplier of all adhesive groups is manufacturing over 100,000 tons of adhesives per year, with around 1200 employees. A global sales structure with 23 Jowat sales organisations plus partner companies is guaranteeing local service with close customer contact. Imprint: Jowat SE Ernst-Hilker-Straße 10 - 14 32758 Detmold Phone: +49 (0) 5231 749-0 E-Mail: [email protected] Data privacy: https://www.jowat.com/en/data-protection/

Engineered to perform Qualicaps® is a global manufacturer of empty pharmaceutical capsules and pharmaceutical processing equipment. With more than 100 years of experience, Qualicaps is a leader in innovation in both Quali-G™ (gelatin) and Quali-V® (hypromellose) capsules, and offers a proprietary product line of pharmaceutical equipment, including capsule filling, band-sealing and inspection machinery. For more information visit www.qualicaps.com.

Based in Cary, NC, Atticus, LLC is an American-owned, bootstrapped and independently operated company. Atticus offers a broad and expanding portfolio of relevant, branded-generic pesticides for Agriculture and EcoCore markets. Driven by grassroots experience and an unwavering commitment to operational excellence, Atticus is an ally uniquely positioned to focus on long-term decisions that benefit retail distribution, the beautification of surroundings and the protection of essential infrastructure. Bringing products to market that complement agronomic and business needs is how Atticus helps retail distributors and end-users get the most out of their input requirements.

Drake Extrusion is North America’s leading manufacturer of colored filament yarn and staple fiber. For over two decades, the name Drake has led the colored polypropylene fiber industry in North America, with research and development based on two continents. Our sister companies IFG Drake, IFG Asota and IFG Exelto have advanced development in high-performance fibers. Located in North America’s textile heartland, we have an unrivaled reputation for excellent customer service, and offer you the personalized service and flexibility of a custom supplier, backed by the resources of our parent company, International Fibres Group. Markets we serve, but are not limited to, are: - Automotive - Home Furnishings - Floor Coverings - GeoTextile - Specialty/Niche Markets

At Asymchem we are proud of the strides that we have made since our founding in 1999, providing R&D and one-stop production services to the world’s top pharmaceutical companies. Driving our success is our commitment to continual optimization and investing in the future. By improving the capabilities our partners need now, and maintaining the agility needed to support innovation, we’ve built a knowledge and experience base that we’re ready to share. Our solutions range from early clinical stage to commercial stage, including R&D and cGMP production of advanced intermediates, APIs, formulations, as well as clinical research services. Through strategic partnerships and calculated business growth, we have built an integrated service ecosystem. Our 8 R&D and manufacturing sites are located in P.R. China and are regularly inspected by regulatory bodies such as the USFDA. Our expertise lies in developing and applying innovative technologies such as green chemistry for scaleup of technically complex API's, with the added advantage of in-house raw materials'​ manufacturing to control availability and lead-times. From initial development of a synthetic chemical process through to manufacturing, Asymchem’s proven team of experienced process and engineering teams has the knowledge to help our clients get things done. Asymchem's toolbox of capabilities include continuous flow reactions technologies, biocatalysis, asymmetric synthesis, HPAPI, cryogenic, catalytic hydrogenation, and others.

Brii Biosciences is a commercial stage biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice. Led by a visionary and experienced leadership team, Brii Bio has deep scientific expertise and a proven ability to progress therapeutic assets from discovery to commercial approval on a consolidated timeline. Established in 2018, Brii Bio now has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. On July 13, 2021, the Company was officially listed on the Hong Kong Stock Exchange under the stock code 2137.HK.